|
Jun 29
|
These 4 Measures Indicate That Bristol-Myers Squibb (NYSE:BMY) Is Using Debt Reasonably Well
|
|
Jun 29
|
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%
|
|
Jun 28
|
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
|
|
Jun 28
|
An Analyst Says Buy, but Bristol-Myers Squibb's Charts Say 'Wait'
|
|
Jun 28
|
K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
|
|
Jun 27
|
Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval
|
|
Jun 26
|
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
|
|
Jun 25
|
3 Healthcare Stocks That Are Too Cheap to Ignore
|
|
Jun 23
|
10 Companies Likely to be Dividend Aristocrats in the Future
|
|
Jun 23
|
Bristol Myers Squibb (BMY) Stock Moves -0.4%: What You Should Know
|
|
Jun 23
|
2 Stocks to Buy With $100 and Hold Forever
|
|
Jun 22
|
I'm Buying These 3 Resilient Stocks During a Bear Market
|
|
Jun 22
|
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
|
|
Jun 21
|
Targeting Eye Disease from a Doctor’s Perspective: Lexitas Pharma CEO George Magrath, Live from NYSE
|
|
Jun 21
|
Leveraging AI in Drug Discovery: Elizabeth Schwarzbach of BigHat Biosciences, Live from NYSE
|
|
Jun 21
|
UPDATE 2-Pharmaceutical trade group sues US over Medicare drug price negotiation plans
|
|
Jun 19
|
Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data
|
|
Jun 17
|
3 Bargain Stocks to Buy on the Dip
|
|
Jun 17
|
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023
|
|
May 25
|
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
|